针对氨基酸载体的阿斯-211标记疗法:克服非小细胞肺癌中药物耐药性
Sifan Feng1, Kentaro Hisada1, Haruna Yorifuji1
1Radiation Biological Chemistry, Department of Chemistry, Graduate School of Science, The University of Osaka, Osaka 560-0043, Japan.
International journal of molecular sciences
|November 13, 2025
概括
针对非小细胞肺癌 (NSCLC) 中的氨基酸载体以α粒子疗法为目标,提供了一种克服治疗耐药性的新方法. 阿斯-211 (Astatine-211 (211At)) 治疗药物显示出消除耐药NSCLC克隆的前景.
科学领域:
- 在瘤学瘤学.
- 核医学就是核医学.
- 分子生物学分子生物学
背景情况:
- 非小细胞肺癌 (NSCLC) 是癌症死亡的主要原因,治疗耐药性是一个重大挑战.
- 通过氨基酸载体 (LAT1,ASCT2,xCT) 的代谢重编程推动NSCLC的生长,存活和免疫逃避.
- 阿尔法粒子疗法,特别是使用阿斯-211 (Astatine-211),通过DNA损伤提供强大的癌细胞杀死.
研究的目的:
- 探索211基于AT的治疗药的潜力,以向氨基酸载体,以克服NSCLC耐药性.
- 评估在临床前NSCLC模型中标记载体配体的疗效.
- 评估这种方法与其他癌症治疗方法的协同作用.
主要方法:
- 在NSCLC模型中标记LAT1向合物的临床前评估.
- 研究与化疗,免疫疗法和铁致死诱导剂的协同效应.
- 使用先进的放射化学和输送系统 (抗体,,纳米载体) 开发治疗术策略.
主要成果:
- 在临床前NSCLC研究中,被标记的载体配体显示出显著的瘤抑制.
- 这些药物在与各种已知的癌症治疗相结合时表现出协同效应.
- 放射化学和输送系统的进步支持NSCLC的超天文框架.
结论:
- 针对氨基酸载体的基于AT的治疗药物代表了打击NSCLC耐药性和异质性的有前途的战略.
- 这种方法提供了一种机理上不同的方法来治疗NSCLC.
- 进一步的开发重点是剂量测量,支架稳定和生物标志物引导的试验,这对临床翻译至关重要.
关键词:
阿斯类药物-211氨基酸运输体 (LAT1,ASCT2,xCT) 的使用药物耐药性 耐药性 药物耐药性代谢重编程是指代谢重编程.非小细胞肺癌的肺癌.放射性药物制品 放射性药物制品有针对性的α粒子疗法.更多相关视频
06:19Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches
Published on: June 16, 2023
3.8K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
17.0K
相关概念视频
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K